Prolonged myocardial stunning after thrombolysis: can left ventricular function be assessed definitely at hospital discharge?

Eur Heart J. 1991 Feb;12(2):214-7. doi: 10.1093/oxfordjournals.eurheartj.a059871.

Abstract

To assess whether myocardial dysfunction after acute reperfusion ('stunning') may show delayed recovery, 33 patients of the European Cooperative Study (rtPA vs placebo) had radionuclide angiocardiography on day 9 and after 3-6 months. Sixteen patients (13 inferior, three anterior infarcts) had a normal left ventricular ejection fraction (LVEF) which remained unchanged (55.4 vs 53.9%). In contrast, LVEF of 17 patients (10 inferior, seven anterior infarcts) with depressed values on day 9 improved during follow-up from 38.8 to 45.2% (P less than 0.01). Improvement was only observed in patients with early reperfusion defined a priori as peak creatine kinase value less than or equal to 15 h of pain onset (from 40.9 to 49.3%; P less than 0.05) in contrast to patients without reperfusion (from 34.0 to 35.2%; ns). Accordingly, LVEF increased in patients with open infarct-related arteries at hospital discharge (n = 8; P = 0.053) but not with persistent occlusion (n = 7; P = 0.11). Thus, a depressed LVEF observed 9 days after reperfusion may show delayed recovery due to prolonged stunning. Therefore, after thrombolysis, left ventricular function may not be evaluated definitively at hospital discharge; results of such studies should be interpreted with caution.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Angioplasty, Balloon, Coronary
  • Aspirin / administration & dosage
  • Combined Modality Therapy
  • Coronary Artery Bypass
  • Coronary Circulation / drug effects
  • Coronary Circulation / physiology*
  • Female
  • Follow-Up Studies
  • Heparin / administration & dosage
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / diagnostic imaging
  • Myocardial Infarction / physiopathology*
  • Myocardial Infarction / therapy
  • Radionuclide Imaging
  • Recombinant Proteins / administration & dosage
  • Recurrence
  • Stroke Volume / drug effects
  • Stroke Volume / physiology*
  • Tissue Plasminogen Activator / administration & dosage*
  • Ventricular Function, Left / drug effects
  • Ventricular Function, Left / physiology*

Substances

  • Recombinant Proteins
  • Heparin
  • Tissue Plasminogen Activator
  • Aspirin